Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
5.68
USD
|
-4.86%
|
|
-7.79%
|
+0.53%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,426
|
1,566
|
288.8
|
278.4
|
390.8
|
-
|
-
|
Enterprise Value (EV)
1 |
1,064
|
1,500
|
21.89
|
24.76
|
93.48
|
61.36
|
84.26
|
P/E ratio
|
-21.5
x
|
-17.7
x
|
-2.25
x
|
-2.12
x
|
-3.58
x
|
-3.12
x
|
-4.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
42.9
x
|
34.2
x
|
9.29
x
|
13.4
x
|
15.3
x
|
15.5
x
|
3.6
x
|
EV / Revenue
|
32.1
x
|
32.8
x
|
0.7
x
|
1.19
x
|
3.65
x
|
2.44
x
|
0.78
x
|
EV / EBITDA
|
-19.2
x
|
-25.4
x
|
-0.22
x
|
-0.23
x
|
-1.2
x
|
-0.74
x
|
-1.14
x
|
EV / FCF
|
-15.7
x
|
-17
x
|
-0.2
x
|
-0.23
x
|
-0.86
x
|
-0.5
x
|
-0.63
x
|
FCF Yield
|
-6.38%
|
-5.88%
|
-509%
|
-438%
|
-116%
|
-201%
|
-159%
|
Price to Book
|
5.08
x
|
4.02
x
|
1
x
|
1.39
x
|
1.62
x
|
2.29
x
|
2.11
x
|
Nbr of stocks (in thousands)
|
43,030
|
48,626
|
48,957
|
49,281
|
68,806
|
-
|
-
|
Reference price
2 |
33.13
|
32.20
|
5.900
|
5.650
|
5.680
|
5.680
|
5.680
|
Announcement Date
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
21.38
|
33.2
|
45.78
|
31.1
|
20.76
|
25.62
|
25.2
|
108.5
|
EBITDA
1 |
-
|
-55.4
|
-59.13
|
-97.84
|
-109.9
|
-78.08
|
-83.16
|
-74.18
|
EBIT
1 |
-
|
-60.45
|
-82.13
|
-129.5
|
-139
|
-127.3
|
-141.2
|
-119.8
|
Operating Margin
|
-
|
-182.1%
|
-179.39%
|
-416.56%
|
-669.84%
|
-497.11%
|
-560.47%
|
-110.48%
|
Earnings before Tax (EBT)
1 |
-
|
-66.96
|
-83.89
|
-128.2
|
-131.2
|
-112.3
|
-145.4
|
-113
|
Net income
1 |
-
|
-66.34
|
-83.89
|
-128.2
|
-132.5
|
-114.4
|
-139.3
|
-117.6
|
Net margin
|
-
|
-199.83%
|
-183.23%
|
-412.19%
|
-638.34%
|
-446.78%
|
-552.64%
|
-108.41%
|
EPS
2 |
-3.670
|
-1.542
|
-1.820
|
-2.620
|
-2.670
|
-1.587
|
-1.818
|
-1.152
|
Free Cash Flow
1 |
-
|
-67.9
|
-88.24
|
-111.4
|
-108.5
|
-108.2
|
-123
|
-133.6
|
FCF margin
|
-
|
-204.55%
|
-192.73%
|
-358.36%
|
-522.96%
|
-422.21%
|
-488.33%
|
-123.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/10/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
20.08
|
7.654
|
13.83
|
6.754
|
2.854
|
3.759
|
2.664
|
11.07
|
3.261
|
3.039
|
5.117
|
7.68
|
5.32
|
-
|
-
|
EBITDA
1 |
-8.579
|
-31.06
|
-26.95
|
-32.07
|
-30.85
|
-35.68
|
-30.68
|
-27.36
|
-30.64
|
-29.33
|
-23.31
|
-20.65
|
-23.75
|
-
|
-
|
EBIT
1 |
-15.26
|
-31.37
|
-27.38
|
-32.49
|
-38.29
|
-36.23
|
-37.57
|
-27.81
|
-37.43
|
-29.78
|
-30.1
|
-28.48
|
-37.2
|
-38
|
-39
|
Operating Margin
|
-75.98%
|
-409.84%
|
-197.95%
|
-481.02%
|
-1,341.73%
|
-963.77%
|
-1,410.21%
|
-251.16%
|
-1,147.72%
|
-979.99%
|
-588.27%
|
-370.77%
|
-699.25%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.66
|
-31.62
|
-27.41
|
-31.96
|
-37.18
|
-34.78
|
-35.92
|
-26.03
|
-34.48
|
-28.36
|
-26
|
-23.47
|
-34.93
|
-
|
-
|
Net income
1 |
-15.66
|
-31.62
|
-27.41
|
-31.96
|
-37.18
|
-34.78
|
-35.92
|
-27.04
|
-34.75
|
-28.36
|
-27.72
|
-26.2
|
-33.91
|
-38
|
-39
|
Net margin
|
-77.99%
|
-413.12%
|
-198.15%
|
-473.17%
|
-1,302.91%
|
-925.25%
|
-1,348.42%
|
-244.19%
|
-1,065.75%
|
-933.23%
|
-541.67%
|
-341.16%
|
-637.35%
|
-
|
-
|
EPS
2 |
-0.3100
|
-0.6500
|
-0.5600
|
-0.6500
|
-0.7600
|
-0.7100
|
-0.7300
|
-0.5500
|
-0.6800
|
-0.4100
|
-0.3924
|
-0.3807
|
-0.4262
|
-0.4300
|
-0.4400
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/8/23
|
11/1/23
|
2/22/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
362
|
65.4
|
267
|
254
|
297
|
329
|
307
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-67.9
|
-88.2
|
-111
|
-109
|
-108
|
-123
|
-134
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-25%
|
-37.8%
|
-49.5%
|
-35.5%
|
-44.2%
|
-59.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-18.5%
|
-27.3%
|
-32.8%
|
-30.4%
|
-64.8%
|
-27.8%
|
Assets
1 |
-
|
-
|
453.5
|
468.8
|
403.6
|
377
|
215
|
423.1
|
Book Value Per Share
2 |
-
|
6.520
|
8.000
|
5.920
|
4.070
|
3.500
|
2.480
|
2.690
|
Cash Flow per Share
2 |
-
|
-
|
-1.890
|
-2.170
|
-2.150
|
0.3300
|
-2.700
|
-0.3700
|
Capex
1 |
-
|
0.65
|
1.28
|
5.5
|
1.71
|
1.5
|
3.23
|
3.78
|
Capex / Sales
|
-
|
1.96%
|
2.79%
|
17.67%
|
8.23%
|
5.86%
|
12.82%
|
3.49%
|
Announcement Date
|
9/10/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
5.68
USD Average target price
17.44
USD Spread / Average Target +207.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.53% | 391M | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B | | -6.26% | 11.42B |
Other Biotechnology & Medical Research
|